Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

• CAR T-cells effectively reduced myeloma growth, even under limited BCMA expression.
• The key metric was cytokine production, specifically IFNγ and IL-2, measured at 24 hours.
• Observational analysis showed cytokine levels in CAR T-cells after co-culturing with K562 tumor cells.
• Findings suggest potential for CAR T-cells in cases with variable BCMA expression, requiring further validation.